OBI Pharma (ROCO:4174) ROE % Adjusted to Book Value: -21.90% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4174 OBI Pharma Inc ROCO:4174
43 GF Score
Price NT$28.40
GF Value NT$138.61
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is OBI Pharma ROE % Adjusted to Book Value?

OBI Pharma ROCO:4174 -1.90% 43 ROE % Adjusted to Book Value is -21.90% as of Dec. 2025. GuruFocus rates ROCO:4174 with a GF Score™ of 43/100 and a GF Value™ of NT$138.61 (Possible Value Trap). The stock has 9 warning signs investors should review.

OBI Pharma's ROE % for the quarter that ended in Dec. 2025 was -82.35%. OBI Pharma's PB Ratio for the quarter that ended in Dec. 2025 was 3.76. OBI Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -21.90%.

OBI Pharma ROE % Adjusted to Book Value Related Terms

OBI Pharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for OBI Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OBI Pharma ROE % Adjusted to Book Value Chart

OBI Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.28 -12.88 -5.93 -15.04 -19.15

OBI Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.40 -12.39 -26.97 -24.64 -21.90

ROCO:4174 vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, OBI Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OBI Pharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OBI Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where OBI Pharma's ROE % Adjusted to Book Value falls into.


ROCO:4174
43GF Score
OBI Pharma Inc ROCO:4174
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OBI Pharma ROE % Adjusted to Book Value Calculation

OBI Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-71.99% / 3.76
=-19.15%

OBI Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-82.35% / 3.76
=-21.90%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -21.90% mean?
OBI Pharma (ROCO:4174) has a ROE % Adjusted to Book Value of -21.90% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OBI Pharma and its competitors.
Is OBI Pharma's ROE % Adjusted to Book Value too high?
OBI Pharma's current ROE % Adjusted to Book Value is -21.90%. Overall, OBI Pharma has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OBI Pharma's ROE % Adjusted to Book Value compare to VRTX and REGN?
OBI Pharma's ROE % Adjusted to Book Value of -21.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OBI Pharma and its competitors. OBI Pharma's current ROE % Adjusted to Book Value is -21.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OBI Pharma stock overvalued right now?
Based on GuruFocus' analysis, OBI Pharma (ROCO:4174) is currently considered Possible Value Trap. The stock's GF Value™ is NT$138.61, compared to a current price of NT$28.40 — trading 79.5% below its estimated fair value. The current ROE % Adjusted to Book Value is -21.90%. OBI Pharma's overall GF Score™ is 43/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For OBI Pharma (ROCO:4174), the current ROE % Adjusted to Book Value is -21.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OBI Pharma (ROCO:4174) Overvalued in 2026?

Based on GuruFocus' analysis, OBI Pharma stock appears to be undervalued. The current stock price of NT$28.40 is trading 79.5% below its estimated GF Value™ of NT$138.61. GuruFocus considers OBI Pharma to be Possible Value Trap.

Key valuation signals for ROCO:4174:

  • ROE % Adjusted to Book Value: -21.90%
  • GF Value™: NT$138.61 vs. price of NT$28.40 (79.5% below fair value)
  • GF Score™: 43/100 with 9 warning signs

No single metric tells the full story. See the ROCO:4174 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OBI Pharma Business Description

Address Zhongxiao East Road, 6th Floor, No. 508, Section 7, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is engaged in the research and development of novel therapeutic agents and biologics for patients with unmet medical needs. The company has three reportable segments: the anti-cancer new drug segment, the botulinum toxin new drug segment, and the CDMO segment. Geographically, it generates the majority of its revenue from Taiwan.
43GF Score

Get the complete analysis for ROCO:4174

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$28.40
Price
NT$138.61
GF Value